These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19930402)

  • 1. Pilot translational study of dietary vitamin C supplementation in Barrett's esophagus.
    Babar M; Abdel-Latif MM; Ravi N; Murphy A; Byrne PJ; Kelleher D; Reynolds JV
    Dis Esophagus; 2010 Apr; 23(3):271-6. PubMed ID: 19930402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia.
    Souza RF
    J Gastroenterol; 2017 Jul; 52(7):767-776. PubMed ID: 28451845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.
    Peng S; Huo X; Rezaei D; Zhang Q; Zhang X; Yu C; Asanuma K; Cheng E; Pham TH; Wang DH; Chen M; Souza RF; Spechler SJ
    Am J Physiol Gastrointest Liver Physiol; 2014 Jul; 307(2):G129-39. PubMed ID: 24852569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential molecular changes in patients with asymptomatic long-segment Barrett's esophagus treated by antireflux surgery or medical therapy.
    Babar M; Ennis D; Abdel-Latif M; Byrne PJ; Ravi N; Reynolds JV
    Am J Surg; 2010 Feb; 199(2):137-43. PubMed ID: 19306979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett's oesophagus.
    Rawat N; Alhamdani A; McAdam E; Cronin J; Eltahir Z; Lewis P; Griffiths P; Baxter JN; Jenkins GJ
    Clin Transl Oncol; 2012 Apr; 14(4):302-11. PubMed ID: 22484638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of the impact of Vitamin C supplementation with neoadjuvant chemoradiation on regulators of inflammation and carcinogenesis in esophageal cancer patients.
    Abdel-Latif MMM; Babar M; Kelleher D; Reynolds JV
    J Cancer Res Ther; 2019; 15(1):185-191. PubMed ID: 30880777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells.
    Huo X; Juergens S; Zhang X; Rezaei D; Yu C; Strauch ED; Wang JY; Cheng E; Meyer F; Wang DH; Zhang Q; Spechler SJ; Souza RF
    Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G278-86. PubMed ID: 21636532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
    Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
    Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
    Tselepis C; Perry I; Dawson C; Hardy R; Darnton SJ; McConkey C; Stuart RC; Wright N; Harrison R; Jankowski JA
    Oncogene; 2002 Sep; 21(39):6071-81. PubMed ID: 12203119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro.
    Jenkins GJ; Harries K; Doak SH; Wilmes A; Griffiths AP; Baxter JN; Parry JM
    Carcinogenesis; 2004 Mar; 25(3):317-23. PubMed ID: 14656946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.
    Abdel-Latif MM; O'Riordan JM; Ravi N; Kelleher D; Reynolds JV
    Dis Esophagus; 2005; 18(4):246-52. PubMed ID: 16128781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus.
    Fountoulakis A; Martin IG; White KL; Dixon MF; Cade JE; Sue-Ling HM; Wild CP
    Dig Dis Sci; 2004 Jun; 49(6):914-9. PubMed ID: 15309877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
    Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
    Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers.
    Jenkins GJ; Mikhail J; Alhamdani A; Brown TH; Caplin S; Manson JM; Bowden R; Toffazal N; Griffiths AP; Parry JM; Baxter JN
    J Clin Pathol; 2007 Nov; 60(11):1232-7. PubMed ID: 17220207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery of zinc to Barrett's metaplasia by oral administration to Barrett's esophagus patients.
    Valenzano MC; Mercado JM; Wang X; Zurbach EP; Raines J; McDonnell E; Morgan M; Farrell C; Rudolph D; Hwang A; Barr M; Cherian D; Bailey R; Raile B; Albert N; Thornton J; Zitin M; Abramson J; Newman G; Daum G; Mercogliano G; Mullin JM
    Ther Deliv; 2014 Mar; 5(3):257-64. PubMed ID: 24592952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus.
    Huo X; Zhang X; Yu C; Cheng E; Zhang Q; Dunbar KB; Pham TH; Lynch JP; Wang DH; Bresalier RS; Spechler SJ; Souza RF
    Gut; 2018 Apr; 67(4):606-615. PubMed ID: 28442495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
    Wang R; Xie J; Shen Y; Ren T
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia.
    Weston AP; Krmpotich P; Makdisi WF; Cherian R; Dixon A; McGregor DH; Banerjee SK
    Am J Gastroenterol; 1996 May; 91(5):981-6. PubMed ID: 8633592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary antioxidants and DNA damage in patients on long-term acid-suppression therapy: a randomized controlled study.
    White KL; Chalmers DM; Martin IG; Everett SM; Neville PM; Naylor G; Sutcliffe AE; Dixon MF; Turner PC; Schorah CJ
    Br J Nutr; 2002 Sep; 88(3):265-71. PubMed ID: 12207836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.